Welcome to our dedicated page for Sensei Biotherapeutics SEC filings (Ticker: SNSE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings for Sensei Biotherapeutics, Inc. (SNSE) provide structured insight into how this clinical stage biotechnology company reports its operations, clinical progress, and corporate actions. Sensei’s common stock is registered on The Nasdaq Stock Market LLC under the symbol SNSE, and the company uses a range of SEC forms to communicate with investors and regulators.
Sensei frequently files Form 8-K to furnish press releases on quarterly financial results and other material events. These filings typically include information on research and development (R&D) and general and administrative (G&A) expenses, cash, cash equivalents and marketable securities, and net loss, along with narrative discussion of clinical milestones. For example, 8-Ks have been used to report financial results for quarters ended March 31, June 30, and September 30, and to attach corresponding press releases as exhibits.
The company also uses Form 8-K to disclose clinical and corporate developments. Filings have furnished press releases on new clinical data for solnerstotug in PD-(L)1 resistant tumors, including presentations at the ESMO Congress, and updates to corporate presentations. Other 8-Ks have described a 1-for-20 reverse stock split intended to help regain compliance with Nasdaq’s minimum bid price requirement and Nasdaq’s subsequent confirmation that Sensei had regained compliance with Listing Rule 5550(a)(2).
A notable 8-K dated October 30, 2025, furnishes a press release announcing that Sensei’s Board of Directors decided to discontinue development of solnerstotug and initiate a strategic review of alternatives, which may include asset sales, licensing, collaborations, a sale of the company, a business combination, a merger, or an orderly wind-down of operations. This filing illustrates how SEC documents capture shifts in corporate strategy and potential changes in the company’s future operations.
On this page, SNSE investors can review Sensei’s SEC filings as they are made available from EDGAR. AI-powered summaries can help explain the key points in lengthy filings, highlight changes in financial condition, and clarify the implications of material events, while the underlying documents remain the authoritative source for detailed information.
Sensei Biotherapeutics (SNSE) filed an 8-K announcing it furnished a press release with financial results for the quarter ended September 30, 2025. The disclosure appears under Item 2.02, with the company stating the information "shall not be deemed filed" for purposes of Section 18 of the Exchange Act.
The press release is included as Exhibit 99.1. Sensei’s common stock trades on Nasdaq under the symbol SNSE.
Sensei Biotherapeutics (SNSE) furnished an update under Item 7.01, announcing it has initiated a strategic review to maximize shareholder value. The company disclosed this via a press release titled “Sensei Biotherapeutics Announces Initiation of Strategic Review to Maximize Shareholder Value,” furnished as Exhibit 99.1. The disclosure is provided under Regulation FD and is not deemed filed under the Exchange Act.
Sensei Biotherapeutics (SNSE) furnished an update via Form 8-K. The company shared a press release titled “Sensei Biotherapeutics Reports New Clinical Results Highlighting Durable Progression Free Survival Data for Solnerstotug in PD-(L)1 Resistant Tumors at the ESMO Congress 2025,” and noted a webcast to discuss the clinical trial results. The company also updated its corporate presentation.
Both the press release (Exhibit 99.1) and the corporate presentation (Exhibit 99.2) were provided under Item 7.01 and are being furnished, not filed, and are not incorporated by reference under the Exchange Act or Securities Act.
What happened: Sensei Biotherapeutics issued a press release announcing its financial results for the quarter ended June 30, 2025.
Why it matters: The press release is attached to this Form 8-K as Exhibit 99.1, so investors can read the company’s reported results and commentary. The filing explicitly states the exhibit is being furnished, not filed, and therefore is not treated the same as a formally filed disclosure or incorporated by reference.
What to do: Review Exhibit 99.1 for the actual figures and management comments, since this 8-K itself does not include the financial numbers.